NYS launches tourism campaign targeted at Canada
Governor Kathy Hochul's office announced on Wednesday the launch of I Love NY's new integrated summer tourism and travel campaign. This is highlighted by two new ads running through August across New York State, and in traditional drive markets including Canada.
Check out great tourism locations across the state with Destination NY
This features advertising across broadcast, streaming and social platforms, and showcases some of the attractions and activities available. The summer campaign also includes I Love NY's largest mobile marketing tour ever, and additional complementary travel industry efforts to promote visitation to the State's 11 different vacation regions.
The multi-layered summer tourism campaign begins with two new ads featuring a new tagline – 'New York State: Everything You Love.' – reflecting the depth and breadth of the world-class attractions and memory-making activities available in communities throughout the state. The new ads can be viewed here and here. More information about planning a summer getaway in the state is available at www.iloveny.com/summer.
Tourism is crucial to New York State, supporting jobs and local economies, and we have so many incredible attractions ready to welcome visitors, from Niagara Falls to Montauk Point. This summer, New York wants to extend a special invitation to travelers from across America and all around the world: this is the perfect opportunity to plan a trip to celebrate history, explore our incredible landscapes, and enjoy all that our incredible state has to offer.
Empire State Development President, CEO and Commissioner Hope Knight
This news comes on the heels of a recent report from United States Senator Charles Schumer's office about a decrease of border crossings from Canada.
A recent survey from North Country Chamber of Commerce survey, 66% of businesses are already experiencing a dip in Canadian bookings. Canada is the top source for international tourism in the United States.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Oil Steadies Near Two-Month Low as IEA Warns of Record Glut
(Bloomberg) -- Oil steadied near a two-month low after the International Energy Agency said the market is on track for record oversupply next year. Brent traded below $66 a barrel, after closing at its lowest since June 5 on Wednesday, while West Texas Intermediate was around $63. The US-Canadian Road Safety Gap Is Getting Wider Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets Gloomy predictions from both the IEA and the US government this week come as supplies from both within and outside OPEC+ are expected to rise into the fourth quarter. Brent's nearest timespread — a guage of market health — is trading at its weakest level since May. Against that backdrop, traders are monitoring the lead-up to Friday's summit between the US and Russian presidents, given that it may result in an easing or tightening of Washington's sanctions on the OPEC+ member. Donald Trump warned he would impose 'very severe consequences' if Vladimir Putin didn't agree to a ceasefire, following a call with European leaders. Oil has lost more than 10% this year as the Organization of the Petroleum Exporting Countries and its partners complete the reversal of output curbs started in 2023, though price moves have been limited in recent days as trading activity eases over the summer months in the northern hemisphere. 'We estimate Brent prices could land in the low $60s if there is progress toward a US-Russia deal,' Citigroup analysts including Anthony Yuen wrote, adding that the most likely outcome of the meeting will 'favor the downside.' --With assistance from Charlie Zhu and Sarah Chen. Americans Are Getting Priced Out of Homeownership at Record Rates Dubai's Housing Boom Is Stoking Fears of Another Crash Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan The Electric Pickup Truck Boom Turned Into a Big Bust ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
NEUPATH HEALTH REPORTS SECOND QUARTER 2025 RESULTS
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and six months ended June 30, 2025 and information regarding the Company's investor webinar on Thursday, August 21, 2025. All figures are in Canadian dollars, unless otherwise noted. 'Our core business continues to perform well, supported by improved capacity utilization, strong early demand for Arthrosamid ®, and the continued focus by the entire NeuPath team on the patient journey and outcomes,' said Joe Walewicz, NeuPath's Chief Executive Officer. 'Adjusting for the benefit of a one-time retroactive payment, we delivered strong growth and improved cash flows that reflect the work of our team to mitigate cost pressures and optimize our clinic footprint. We expect further investments in the second half of the year to enhance our clinic network, and with the addition of Stephen Lemieux as President, we are accelerating our focus on strategic opportunities. We believe we are well-positioned for continued growth in the second half of 2025 and beyond.' Financial and Operational Highlights Record total revenue of $23.6 million and $43.0 million for the three and six months ended June 30, 2025, up 25% and 18% year-over-year; Adjusted EBITDA was $2.2 million and $3.5 million for the three and six months ended June 30, 2025, up 69% and 61% year-over-year; For the six months ended June 30, 2025, capacity utilization improved to 79%, up from 75% for the six months ended June 30, 2024; As at June 30, 2025, the Company had $3.8 million in cash and cash equivalents and interest-bearing long-term debt of $6.5 million; and Following the launch of Arthrosamid (2.5% iPAAG) in March, there was substantial uptake in Q2, with continued patient interest in this novel procedure. Q2 2025 Financial Results Total Revenue Total revenue is comprised of clinic revenue and non-clinic revenue. Total revenue was $23.6 million and $43.0 million for the three and six months ended June 30, 2025 compared to $18.9 million and $36.4 million for the three and six months ended June 30, 2024. Clinic Revenue Clinic revenue is generated through the provision of medical services to patients. Clinic revenue was $22.2 million and $40.3 million for the three and six months ended June 30, 2025 compared to $17.3 million and $33.4 million for the three and six months ended June 30, 2024. The increase in clinic revenue for the three and six months ended June 30, 2025 was primarily due to positive adjustments to physician reimbursement rates including a material one-time payment in the quarter related to prior period physician reimbursements and stronger revenues from fluoroscopy. Capacity utilization was 84% and 79% for the three and six months ended June 30, 2025 compared to 77% and 75% in the three and six months ended June 30, 2024. The improvement in capacity utilization was primarily driven by stronger revenues and the continued optimization of clinic space. Non-clinic Revenue Non-clinic revenue was $1.4 million and $2.7 million for the three and six months ended June 30, 2025 compared to $1.6 million and $2.9 million for the three and six months ended June 30, 2024. Non-clinic revenue is earned from physician staffing allocation services where the Company provides physicians for provincial and federal correctional institutions across Canada, and from contract research services provided to pharmaceutical companies and clinical research organizations. This revenue fluctuates depending on the need for physicians in certain institutions and the timing and enrolment of clinical studies that the Company is working on. Gross margin % was 19.8% and 19.4% for the three and six months ended June 30, 2025 compared to 20.0% and 19.3% for the three and six months ended June 30, 2024. The increase in gross margin during the current three and six-month periods was primarily driven by positive adjustments to physician reimbursement rates including a material one-time payment in the quarter related to prior period physician reimbursements and stronger revenues from fluoroscopy (see Non-IFRS Financial Measures - Gross Margin and Gross Margin %). Adjusted EBITDA was $2.2 million and $3.5 million for the three and six months ended June 30, 2025 compared to $1.3 million and $2.2 million for the three and six months ended June 30, 2024. Liquidity and Capital Resources As at June 30, 2025, the Company's net debt was $2.7 million, an improvement from $3.1 million as at June 30, 2024. The Company's net debt as at June 30, 2025 consisted of $3.8 million of cash and cash equivalents and long-term debt of $6.5 million compared to $2.9 million of cash and cash equivalents and long-term debt of $6.0 million as at June 30, 2024. For more information see Note 5, Long-Term Debt in the Company's Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2025, and Note 6, Long-Term Debt in the Company's Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2024. Non-IFRS Financial and Other Measures The Company discloses non-IFRS measures (such as EBITDA, Adjusted EBITDA, and gross margin) and non-IFRS ratios (such as gross margin %) that do not have standardized meanings prescribed by International Financial Reporting Standards ('IFRS'). The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-IFRS financial measures and other measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other reporting issuers and therefore unlikely to be comparable to similar measures presented by other companies. Furthermore, these non-IFRS measures and other measures should not be considered in isolation or as a substitute for measures of performance or cash flows as prepared in accordance with IFRS. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS. EBITDA and Adjusted EBITDA EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines Adjusted EBITDA, as EBITDA, excluding stock-based compensation expense, executive long-term performance and retention bonus, restructuring costs, gain on derecognition of other obligations, fair value adjustments, transaction costs, impairment charges, gain on sale of building, government loans forgiveness, finance income and loss or gain on sale of property, plant and equipment. Management believes EBITDA and Adjusted EBITDA are useful supplemental non-GAAP measures to determine the Company's ability to generate cash available for operations, working capital, capital expenditures, debt repayments, interest expense and income taxes. The following table provides a reconciliation of net and comprehensive income to EBITDA and Adjusted EBITDA: Gross Margin and Gross Margin % Management believes gross margin and gross margin % are important supplemental non-GAAP measures for evaluating operating performance and to allow for operating performance comparability from period-to-period. Gross margin is calculated as total revenue minus cost of medical services ('COMS'). Gross margin % is calculated as gross margin divided by total revenue. The following table provides a reconciliation of total revenue to gross margin: Three months ended June 30 Six months ended June 30 2025 2024 2025 2024 $ $ $ $ Clinic revenue 22,209 17,266 40,255 33,434 Non-clinic revenue 1,421 1,614 2,710 2,932 Total revenue 23,630 18,880 42,965 36,366 Cost of medical services 18,951 15,096 34,646 29,349 Gross margin (1) 4,679 3,784 8,319 7,017 Gross margin % (1) 19.8% 20.0% 19.4% 19.3% Expand (1) Gross margin and gross margin % are non-IFRS measures. Please refer to Non-IFRS Financial Measures above. Expand For further details on the results, please refer to NeuPath's Management, Discussion and Analysis and Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2025, which are available on the Company's website ( and under the Company's profile on SEDAR+ ( Notice of Investor Webinar Event: Presentation and Q&A Webinar with NeuPath Health Inc. (NPTH) Presentation Date & Time: Thursday, August 21, 2025 at 10:00 AM ET / 7:00 AM PT Webcast Registration Link: About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit Forward-Looking Statements This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of continued operational improvements in 2025 and the execution of the Company's growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's Annual Information Form dated March 26, 2025 filed on SEDAR + under the Company's profile at Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forbes
an hour ago
- Forbes
How Trade Wars And Interest Rates Are Reshaping Canadian Investments
Elie Nour, CEO at Nour Private Wealth (NPW). In 2025, Canadian investors face unprecedented challenges and opportunities. While many continue to rely on investment strategies that served them well over the past decade, the convergence of global trade tensions and monetary policy shifts demands a fundamental reconsideration of how wealth is built and preserved. The investment environment you navigated just 18 months ago bears little resemblance to today's reality. The New Economic Chessboard Trade wars between major economies intensified in 2024 and into this year, creating ripple effects that directly impact Canadian portfolios across global markets. These geopolitical tensions represent structural changes to investment fundamentals that many advisors have yet to incorporate fully into their recommendations. Consider the case of a typical Toronto-based investor with exposure to multinational corporations. The second-order effects of tariff escalations have transformed the profit potential of these formerly reliable performers, with supply chain restructuring costs possibly eliminating much of their margin advantages. What once represented portfolio stability may now introduce unexpected volatility. At the same time, the Bank of Canada's rate cut cycle has created a deceptive environment for fixed-income investors. The initial euphoria of rate reductions masks significant challenges in achieving meaningful returns through traditional bond allocations. The Canadian Advantage: Overlooked Sectors The current economic realignment presents uniquely Canadian opportunities that remain underappreciated by mainstream investment analysis. Resource sovereignty is a critical economic factor in 2025. Canadian companies positioned at the intersection of essential minerals, clean energy infrastructure and advanced manufacturing are experiencing structural tailwinds that transcend typical market cycles. Take, for example, a forestry and metals conglomerate based in British Columbia. By pivoting toward materials essential for the energy transition, this formerly cyclical business has secured preferential status in North American supply chains, fundamentally altering its risk-return profile. Interest Rate Illusions The Bank of Canada's monetary policy requires sophisticated interpretation, with experts mixed about the likelihood of another rate cut in the near future. While declining rates typically signal opportunity in specific sectors, the current environment demands nuance in execution. Many wealth management strategies naively assume that rate cuts automatically benefit all equities equally. This superficial analysis overlooks how the causes of rate adjustments impact different business models asymmetrically. Companies with strong pricing power and low capital intensity demonstrate particular resilience in this environment. One often-overlooked consideration is that the impact of rate cuts on financial institutions varies dramatically based on their loan book composition and duration structure. Regional Canadian banks with appropriate positioning present compelling value propositions that larger financial institutions cannot match. Portfolio Construction For Canadian Realities Conventional portfolio construction fails to account for the specific challenges facing Canadian investors this year. The traditional 60/40 stock/bond allocation requires significant modification to thrive in current conditions. Strategic defensive positioning must be balanced with targeted exposure to sectors benefiting from emerging economic patterns. This is not about radical portfolio overhauls but rather thoughtful recalibration based on forward-looking analysis. What does this mean practically? Consider a professional couple in their 40s with a seven-figure portfolio. Their optimal allocation now might include increased exposure to Canadian mid-cap companies with strong domestic supply chains, complemented by select positions in businesses benefiting from nearshoring trends. The fixed income portion requires particular attention, with duration management becoming increasingly crucial. Duration management involves selecting bonds with suitable maturities to balance risk and income. Bonds with shorter durations tend to reduce interest rate sensitivity and maintain reinvestment flexibility. Bonds with longer durations, meanwhile, tend to favor environments where rates are expected to drop—especially if these bonds feature a high yield. Wealth Preservation Through Strategic Adaptation The current environment rewards strategic adaptability rather than reactive adjustments. High-net-worth Canadians should consider three specific adjustments to their investment approach: 1. Reassess geographic allocations, with particular attention to domestic opportunities that are insulated from trade disruptions. The conventional wisdom of broad international diversification requires refinement in an era of economic fragmentation. 2. Implement sector rotation strategies that capitalize on the transition from interest rate sensitivity to trade resilience as the dominant market factor. Sector rotation involves shifting investments between sectors based on economic cycles. This might mean reducing exposure to defensive sectors such as healthcare and consumer staples and increasing exposure to sectors that thrive in periods of expansion and growth, such as technology and consumer discretionary. This shift is particularly relevant for the Canadian energy and materials sectors. 3. Introduce alternative income streams beyond traditional fixed income. Private credit opportunities with appropriate risk parameters can provide yield advantages that public markets cannot currently match. The Total Wealth Picture Sophisticated wealth management extends beyond portfolio construction to encompass a broader range of financial planning considerations. In the current environment, the tax implications of investment decisions are particularly important. Canadian investors face a distinctive set of tax considerations that international investment advice often overlooks. Considerations include tax implications for domestic (and foreign) dividends, interest income and capital gains (and losses); the incorporation of registered accounts to optimize overall tax efficiency; and the strategic use of federal and provincial tax deductions and credits. Coordinating registered and non-registered accounts becomes increasingly important as the characteristics of interest and dividend income evolve in response to changing monetary policy. Positioning For Resilience And Opportunity The convergence of trade tensions and shifts in monetary policy creates a challenging environment for Canadian investors. Yet within this complexity lie significant opportunities for those who recognize evolving economic patterns. The key to positive investment outcomes in such times lies in applying proven investment principles with greater sophistication and awareness of current realities. Canadian investors who adapt their strategies to incorporate these insights position themselves to capitalize on emerging opportunities in this transformed investment landscape. The information provided here is not investment, tax or financial advice. You should consult with a licensed professional for advice concerning your specific situation. Forbes Finance Council is an invitation-only organization for executives in successful accounting, financial planning and wealth management firms. Do I qualify?
